Designation of the project | spinit® CRISPR
Project Code | POCI-01-0247-FEDER-033778
Main goal | Reinforce research, technology development and innovation
Region of activity | Alentejo
Beneficiary | biosurfit S.A.

Approval date | 15-01-2019
Start date | 01-06-2019
End date | 31-05-2022
Total eligible value | 1.875.598,94 €
EU Financing | 1.150.170,87 €

Project summary
On a co-promotion initiative, the project presents the development of a rapid diagnostic test panel of Dengue, Zika and Chikungunya febrile syndromes. The grant supports all R&D developments and the translation of multiplexed molecular isothermal amplification techniques to a lab-on-a-disc device and subsequent analytical and clinical validation.

Strategic goals

• Make the spinit® technology a global solution being one of the top players in the PoC diagnostic market;

• Attract intelligent and international strategic investment to maintain national production and generate investment;

• Create and develop an R&D and manufacture centre with a specialized team contributing to the country’s development and supporting the launch of new projects at the diagnostics market; - Continuously invest in technological innovation to solve key technical problems, contributing to a reduction of costs and improvement of diagnostic performance; 

• Actively participate in the development of the companion diagnostics and assisted living with remote clinical monitoring, through the development and launch in the market of diagnostic solutions with high performance and reduced investment for the end users and their integration with the health systems.